Cyteir Therapeutics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

-21.6%

Kazanç büyüme oranı

80.9%

EPS büyüme oranı

Biotechs Sektör Büyümesi	17.0%
Gelir büyüme oranı	n/a
Özkaynak getirisi	-26.6%
Net Marj	n/a
Son Kazanç Güncellemesi	30 Sep 2023

Yakın geçmiş performans güncellemeleri

Güncelleme yok

Recent updates

Is Cyteir Therapeutics (NASDAQ:CYT) In A Good Position To Deliver On Growth Plans?

Oct 25

Cyteir Therapeutics GAAP EPS of -$0.34

Aug 08

Cyteir Therapeutics (NASDAQ:CYT) Is In A Good Position To Deliver On Growth Plans

Jul 21

Here's Why We're Not Too Worried About Cyteir Therapeutics' (NASDAQ:CYT) Cash Burn Situation

Apr 21

Companies Like Cyteir Therapeutics (NASDAQ:CYT) Are In A Position To Invest In Growth

Jan 06

We're Not Very Worried About Cyteir Therapeutics' (NASDAQ:CYT) Cash Burn Rate

Sep 21

Cyteir Therapeutics closes lower on first day of trading

Jun 18

Gelir ve Gider Dağılımı

Cyteir Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

OTCPK:CYTT Gelir, gider ve kazançlar (USD Millions )
Tarih	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Sep 23	-33	12	22
30 Jun 23	-41	13	27
31 Mar 23	-44	14	31
31 Dec 22	-46	15	34
30 Sep 22	-49	15	35
30 Jun 22	-50	15	35
31 Mar 22	-49	14	35
31 Dec 21	-42	11	31
30 Sep 21	-36	9	39
30 Jun 21	-29	6	31
31 Mar 21	-22	5	22
31 Dec 20	-21	4	17
31 Dec 19	-15	3	0

Cyteir Therapeutics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Recent updates

Cyteir Therapeutics Files Form 15

Cyteir Announces Timeline for Voluntarily Delisting from Nasdaq

Cyteir Therapeutics, Inc. Announces Resignation of Timothy Romberger from Board of Directors

Cyteir Therapeutics, Inc. Announces Board Changes

Cyteir Therapeutics, Inc. Presents Ongoing Results from a Dose Expansion Cohort of CYT-0851 in Combination with Capecitabine in Advanced Platinum-Resistant Ovarian Cancer

Cyteir Therapeutics to Delist Its Shares of Common Stock from the Nasdaq Global Select Market Upon the Approval of Plan of Dissolution

Cyteir Therapeutics, Inc. Presents Results from A Phase 1 Study with CYT-0851

Price target decreased by 36% to US$2.33

Cyteir Therapeutics, Inc. Announces the Promotion of David Gaiero to Chief Financial Officer

Cyteir Therapeutics Announces Prioritization of CYT-0851 Development

Cyteir Therapeutics, Inc. Announces Executive Changes

President exercised options to buy US$193k worth of stock.

Price target decreased to US$5.33

Is Cyteir Therapeutics (NASDAQ:CYT) In A Good Position To Deliver On Growth Plans?

Cyteir Therapeutics GAAP EPS of -$0.34

Cyteir Therapeutics (NASDAQ:CYT) Is In A Good Position To Deliver On Growth Plans

Cyteir Therapeutics, Inc.(NasdaqGS:CYT) dropped from Russell 2500 Value Index

Cyteir Therapeutics, Inc. Announces CYT-0851 Phase 1 Dose Escalation Results Show Early Clinical Activity and Generally Well Tolerated Safety Profile in Advanced Solid Tumors and Hematologic Malignancies

Key Executive recently bought US$95k worth of stock

Cyteir Therapeutics Appoints Adam Veness as General Counsel

Cyteir Therapeutics, Inc. Names Krisztina Nemenyi as Senior Vice President of Regulatory Affairs and Quality

Cyteir Therapeutics, Inc., Annual General Meeting, Jun 15, 2022

Here's Why We're Not Too Worried About Cyteir Therapeutics' (NASDAQ:CYT) Cash Burn Situation

Cyteir Therapeutics, Inc. Announces Board Changes

Cyteir Therapeutics, Inc. Announces the Appointment of Stephen Sands to Board of Directors

Cyteir Therapeutics Announces First Patient Dosed in Phase 2 with CYT-0851

Cyteir Therapeutics Inc. Announces the Appointment of John F. Thero to Board of Directors

Cyteir Therapeutics Announces First Patient Dosed in Phase 1 Combination Trial With CYT-0851

Companies Like Cyteir Therapeutics (NASDAQ:CYT) Are In A Position To Invest In Growth

We're Not Very Worried About Cyteir Therapeutics' (NASDAQ:CYT) Cash Burn Rate

Cyteir Therapeutics, Inc. has completed an IPO in the amount of $133.2 million.

Cyteir Therapeutics closes lower on first day of trading

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin